Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2013

01.01.2013 | Review

Trastuzumab administration during pregnancy: a systematic review and meta-analysis

verfasst von: Flora Zagouri, Theodoros N. Sergentanis, Dimosthenis Chrysikos, Christos A. Papadimitriou, Meletios-Athanassios Dimopoulos, Rupert Bartsch

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Landmark studies have established trastuzumab in the treatment of HER2-positive breast cancer. The present systematic review and meta-analysis aims to synthesize all available data, so as to evaluate the safety of trastuzumab during pregnancy. This study was performed in accordance with the PRISMA guidelines. All studies that examined the safety of trastuzumab administered during pregnancy, regardless of sample size, were considered eligible. Overall, 17 studies (18 pregnancies; 19 newborns) were included. In 55.6 % of cases, trastuzumab was administered in the metastatic setting. The mean duration of trastuzumab administration was 14.8 weeks. Occurrence of oligohydramnios/anhydramnios (O/A) was the most common (61.1 %) adverse event. 73.3 % of pregnancies exposed to trastuzumab during the second/third trimester were complicated with O/A; the respective rate of pregnancies exposed to trastuzumab exclusively during the first trimester was 0 % (P = 0.043). The mean GA at delivery was 33.8 weeks, and the mean weight of babies at delivery was 2,261 gr. In 52.6 % of cases, a healthy neonate was born. At the long-term evaluation, all children without problems at birth were healthy with a median follow-up of 9 months, while four out of nine children facing troubles at birth were dead within an interval ranging between birth and 5.25 months. All children exposed to trastuzumab in utero exclusively in the first trimester were completely healthy at birth. Trastuzumab should not be administered during pregnancy. However, for women who become accidentally pregnant during trastuzumab administration and wish to continue pregnancy, trastuzumab should be stopped and pregnancy could be allowed to continue.
Literatur
1.
Zurück zum Zitat Pentheroudakis G, Orecchia R, Hoekstra HJ et al (2010) Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v266–v273PubMedCrossRef Pentheroudakis G, Orecchia R, Hoekstra HJ et al (2010) Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v266–v273PubMedCrossRef
2.
Zurück zum Zitat Mir O, Berveiller P, Ropert S et al (2008) Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 19:607–613PubMedCrossRef Mir O, Berveiller P, Ropert S et al (2008) Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 19:607–613PubMedCrossRef
4.
Zurück zum Zitat Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236–244PubMedCrossRef Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236–244PubMedCrossRef
5.
Zurück zum Zitat Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRef
6.
Zurück zum Zitat Untch M, Fasching PA, Konecny GE et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351–3357PubMedCrossRef Untch M, Fasching PA, Konecny GE et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351–3357PubMedCrossRef
7.
Zurück zum Zitat Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149–156PubMedCrossRef Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149–156PubMedCrossRef
8.
Zurück zum Zitat Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29:264–271PubMedCrossRef Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29:264–271PubMedCrossRef
10.
Zurück zum Zitat Azim HA Jr, Azim H, Peccatori FA (2010) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 6:821–826PubMedCrossRef Azim HA Jr, Azim H, Peccatori FA (2010) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 6:821–826PubMedCrossRef
11.
Zurück zum Zitat Abusief ME, Missmer SA, Ginsburg ES et al (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116:791–798PubMedCrossRef Abusief ME, Missmer SA, Ginsburg ES et al (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116:791–798PubMedCrossRef
12.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34PubMedCrossRef Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34PubMedCrossRef
13.
Zurück zum Zitat Gottschalk I, Berg C, Harbeck N et al (2011) Fetal renal insufficiency following trastuzumab treatment for breast cancer in pregnancy: case report und review of the current literature. Breast Care (Basel) 6:475–478CrossRef Gottschalk I, Berg C, Harbeck N et al (2011) Fetal renal insufficiency following trastuzumab treatment for breast cancer in pregnancy: case report und review of the current literature. Breast Care (Basel) 6:475–478CrossRef
14.
Zurück zum Zitat El-Safadi S, Wuesten O, Muenstedt K (2012) Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res 38:589–592CrossRef El-Safadi S, Wuesten O, Muenstedt K (2012) Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res 38:589–592CrossRef
15.
Zurück zum Zitat Mandrawa CL, Stewart J, Fabinyi GC et al (2011) A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol 51:372–376PubMedCrossRef Mandrawa CL, Stewart J, Fabinyi GC et al (2011) A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol 51:372–376PubMedCrossRef
16.
Zurück zum Zitat Goodyer MJ, Ismail JR, O’Reilly SP et al (2009) Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J 2:9329PubMedCrossRef Goodyer MJ, Ismail JR, O’Reilly SP et al (2009) Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J 2:9329PubMedCrossRef
17.
Zurück zum Zitat Beale JM, Tuohy J, McDowell SJ (2009) Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 201:e13–e14PubMedCrossRef Beale JM, Tuohy J, McDowell SJ (2009) Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 201:e13–e14PubMedCrossRef
18.
Zurück zum Zitat Weber-Schoendorfer C, Schaefer C (2008) Trastuzumab exposure during pregnancy. Reprod Toxicol 25:390–391; author reply 392 Weber-Schoendorfer C, Schaefer C (2008) Trastuzumab exposure during pregnancy. Reprod Toxicol 25:390–391; author reply 392
19.
Zurück zum Zitat Pant S, Landon MB, Blumenfeld M et al (2008) Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 26:1567–1569PubMedCrossRef Pant S, Landon MB, Blumenfeld M et al (2008) Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 26:1567–1569PubMedCrossRef
20.
Zurück zum Zitat Witzel ID, Müller V, Harps E et al (2008) Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 19:191–192PubMedCrossRef Witzel ID, Müller V, Harps E et al (2008) Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 19:191–192PubMedCrossRef
21.
Zurück zum Zitat Sekar R, Stone PR (2007) Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 110:507–510PubMedCrossRef Sekar R, Stone PR (2007) Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 110:507–510PubMedCrossRef
22.
Zurück zum Zitat Shrim A, Garcia-Bournissen F, Maxwell C et al (2007) Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy- Case report and updated literature review. Reprod Toxicol 23:611–613PubMedCrossRef Shrim A, Garcia-Bournissen F, Maxwell C et al (2007) Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy- Case report and updated literature review. Reprod Toxicol 23:611–613PubMedCrossRef
23.
Zurück zum Zitat Bader AA, Schlembach D, Tamussino KF et al (2007) Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 8:79–81PubMedCrossRef Bader AA, Schlembach D, Tamussino KF et al (2007) Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 8:79–81PubMedCrossRef
24.
Zurück zum Zitat Waterston AM, Graham J (2006) Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 24:321–322PubMedCrossRef Waterston AM, Graham J (2006) Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 24:321–322PubMedCrossRef
25.
Zurück zum Zitat Fanale MA, Uyei AR, Theriault RL et al (2005) Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6:354–356PubMedCrossRef Fanale MA, Uyei AR, Theriault RL et al (2005) Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6:354–356PubMedCrossRef
26.
Zurück zum Zitat Watson WJ (2005) Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105:642–643PubMedCrossRef Watson WJ (2005) Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105:642–643PubMedCrossRef
27.
Zurück zum Zitat Azim HA Jr, Peccatori FA, Liptrott SJ et al (2009) Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol 6:367–370PubMedCrossRef Azim HA Jr, Peccatori FA, Liptrott SJ et al (2009) Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol 6:367–370PubMedCrossRef
28.
Zurück zum Zitat Warraich Q, Smith N (2009) Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol 29:147–148PubMedCrossRef Warraich Q, Smith N (2009) Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol 29:147–148PubMedCrossRef
29.
Zurück zum Zitat Roberts NJ, Auld BJ (2010) Trastuzamab (Herceptin)-related cardiotoxicity in pregnancy. J R Soc Med 103:157–159PubMedCrossRef Roberts NJ, Auld BJ (2010) Trastuzamab (Herceptin)-related cardiotoxicity in pregnancy. J R Soc Med 103:157–159PubMedCrossRef
30.
Zurück zum Zitat Azim HA Jr, Peccatori FA, Pavlidis N (2010) Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev 36:101–109PubMedCrossRef Azim HA Jr, Peccatori FA, Pavlidis N (2010) Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev 36:101–109PubMedCrossRef
31.
Zurück zum Zitat Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 83:234–238PubMedCrossRef Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 83:234–238PubMedCrossRef
32.
Zurück zum Zitat Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer [Epub Ahead of print] Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer [Epub Ahead of print]
33.
Zurück zum Zitat Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86:328–344PubMedCrossRef Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86:328–344PubMedCrossRef
34.
Zurück zum Zitat Malek A (2003) Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 21:3362–3364PubMedCrossRef Malek A (2003) Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 21:3362–3364PubMedCrossRef
35.
Zurück zum Zitat Kilpatrick SJ (1997) Therapeutic interventions for oligohydramnios: amnioinfusion and maternal hydration. Clin Obstet Gynecol 40:328–336PubMedCrossRef Kilpatrick SJ (1997) Therapeutic interventions for oligohydramnios: amnioinfusion and maternal hydration. Clin Obstet Gynecol 40:328–336PubMedCrossRef
36.
37.
Zurück zum Zitat Goodyer PR, Cybulsky A, Goodyer C (1993) Expression of the epidermal growth factor receptor in fetal kidney. Pediatr Nephrol 7:612–615PubMedCrossRef Goodyer PR, Cybulsky A, Goodyer C (1993) Expression of the epidermal growth factor receptor in fetal kidney. Pediatr Nephrol 7:612–615PubMedCrossRef
38.
Zurück zum Zitat Jokhi PP, King A, Loke YW (1994) Reciprocal expression of epidermal growth factor receptor (EGF-R) and c-erbB2 by non-invasive and invasive human trophoblast populations. Cytokine 6:433–442PubMedCrossRef Jokhi PP, King A, Loke YW (1994) Reciprocal expression of epidermal growth factor receptor (EGF-R) and c-erbB2 by non-invasive and invasive human trophoblast populations. Cytokine 6:433–442PubMedCrossRef
39.
Zurück zum Zitat Lee KF, Simon H, Chen H et al (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394–398PubMedCrossRef Lee KF, Simon H, Chen H et al (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394–398PubMedCrossRef
40.
Zurück zum Zitat Azim HA Jr, Metzger-Filho O, de Azambuja E et al (2012) Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01–01). Breast Cancer Res Treat 133:387–391PubMedCrossRef Azim HA Jr, Metzger-Filho O, de Azambuja E et al (2012) Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01–01). Breast Cancer Res Treat 133:387–391PubMedCrossRef
Metadaten
Titel
Trastuzumab administration during pregnancy: a systematic review and meta-analysis
verfasst von
Flora Zagouri
Theodoros N. Sergentanis
Dimosthenis Chrysikos
Christos A. Papadimitriou
Meletios-Athanassios Dimopoulos
Rupert Bartsch
Publikationsdatum
01.01.2013
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2013
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-2368-y

Weitere Artikel der Ausgabe 2/2013

Breast Cancer Research and Treatment 2/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.